Pharmasset, Inc. Company Profile
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.
303-A College Road East
United States of America
Phone: (609) 613-4100
Fax: (609) 613-4150
A former Bristol-Myers Squibb executive who pleaded guilty to insider trading was sentenced on Wednesday to one year in prison and a $10,000 fine. Robert Ramnarine, 46, a former execu...
ByPharma Reports:Last week, the FDA approved Gilead Sciences' (GILD) Sovaldi for hepatitis C. The approval was very much anticipated, nevertheless, since we have developed a deep interest in tracking...
Drugs and Medications
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...
More Information about "Pharmasset, Inc." on BioPortfolio
We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.